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Background: Non-invasive imaging of peritoneal carcinomatosis remains challenging. The aim of this study was to
compare positron emission tomography (PET) and bioluminescence imaging (BLI) for the early detection of
peritoneal carcinomatosis in a mouse model.
Methods: Female nude mice were inoculated intraperitoneally with 1×107 HSC45-M2-luc gastric cancer cells. The
cells were stably transfected with the gene coding for firefly luciferase. Tumour development was monitored using
PET and BLI and in two subgroups, on days 3 and 4 or on days 6 and 7 after tumour cell inoculation. Tumour
nodules found on post mortem examination served as the reference standard for evaluating the images.
Results: PET detected 58/82 lesions (sensitivity 71 %). This method detected all (100 %) nodules larger than 6 mm,
88 % of nodules in the range of >2–4 mm, and even 58 % of small nodules measuring only 1–2 mm. BLI identified
a total of 40/82 lesions (sensitivity 49 %). The difference between PET and BLI was statistically significant at p < 0.05
(PET/BLI chi-square 8.2).
Conclusions: PET was more sensitive than BLI for the detection of early peritoneal carcinomatosis in our mouse
model. The sensitivity of BLI largely depended on the site of the lesions in relation to the imaging device.
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Worldwide, gastric cancer is one of the most common
malignancies. Despite recent advances in diagnosis and
therapy, the prognosis of patients with gastric cancer re-
mains poor [1]. Gastric cancer is often diagnosed in a lo-
cally advanced stage because of the lack of symptoms.
Lymphatic and haematogenous spread may, however, be
present even in the early stages [2]. Curative treatment is
therefore possible in only approximately 50 % of patients.
Even after potentially curative surgery (R0 resections),
many patients develop recurrent disease, for which the
treatment options are very limited [3].
One of the most severe conditions with initial gas-
tric cancer spread or recurrent disease is peritoneal* Correspondence: jens.stollfuss@t-online.de
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the Creative Commons license, and indicate ifcarcinomatosis, which has a median overall survival
time of 3.1 months [4]. Sensitive detection and monitor-
ing of peritoneal carcinomatosis is therefore essential for
the initial staging and adequate treatment planning.
As a functional imaging modality, positron emission
tomography (PET) with F18-flurodeoxyglucose (18 F-FDG)
may represent an alternative to conventional imaging
methods, such as CT and MRI, which are based mainly on
the morphology. It has already been used for the staging
and follow-up of various malignancies and has also been
shown to provide additional information in the detection
of peritoneal carcinomatosis [5].
Bioluminescence imaging (BLI) is a non-invasive im-
aging modality that has been developed over the last dec-
ade. It uses light emission produced by firefly (Photinus
pyralis) luciferase in the presence of ATP and oxygen, fol-
lowing injection of the substrate D-luciferin. The emitted
light is visualised by a cooled charge-coupled device
(CCD) camera. This method has been successfully appliedis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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growth and therapeutic response [6].
To the best of our knowledge few data that would allow
the evaluation of PET and BLI have yet been obtained in a
single animal study. The aim of the present study was
therefore to compare bioluminescence imaging and posi-
tron emission tomography for the early detection of peri-
toneal carcinomatosis in a mouse model.
Methods
Cell line
K. Yanagihara of the National Cancer Center Research
Institute, Chuo-ku, Tokyo, kindly provided the human
signet ring cell line HSC45-M2. It was isolated from the
ascites and pleural effusion of a patient with a diffuse
type of gastric cancer [7].
Luciferase transfection
Plasmid construction
The coding sequence of firefly luciferase (fluc) was excised
from pGL3 basic vector (Promega, Mannheim, Germany)
by Hind III and Xba I digestion, blunted and ligated into
the blunted Xho I site of the plasmid pcDNA3.1 (Invitro-
gen, Karlsruhe, Germany). The integrity of the cloned se-
quence (pcDNA3.1-fluc) was confirmed by automated
DNA sequencing (GATC, Konstanz, Germany) using an
ABI Prism 377 DNA sequencer (Applied Biosystems,
Darmstadt, Germany).
Stable transfection of HSC cells
HSC cells were stably transfected with the expression
vector pcDNA3.1-fLuc under the control of the cyto-
megalovirus promoter. Confluent cells were incubated in
six-well plates with 0.8 g of pcDNA3.1-fluc, 20 μl Effec-
tene and 6.4 μl enhancer per well, according to the man-
ufacturer’s instructions (Qiagen, Hilden, Germany).
Stable fluc-expressing HSC45-M2 cell clones were se-
lected by treatment with 800 μg/ml Geneticin. The
luciferase-transfected HSC45-M2 cells were grown in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented
with 10 % fetal calf serum, 1 % penicillin/streptomycin
(10,000 IU/10 mg/ml) and Geneticin (800 μg/ml), at 37 °C
in a humidified atmosphere with 5 % CO2.
Animal model
Sixteen 7-week-old female NMRI nude mice were given
intraperitoneal (i.p.) inoculations of 1*107 HSC45-M2-luc
gastric cancer cells dissolved in 0.5 ml DMEM. The ani-
mals were divided into two groups (I and II) consisting of
eight mice each. Imaging with PET and BLI was per-
formed either on days 3 and 4 after inoculation (group I)
or on days 6 and 7 (group II). One mouse died shortly
after inoculation, leaving 15 mice available for analysis.A mixture of 82 % saline, 10 % Ketavet [ketamine],
and 8 % Rompun [xylazine] was used for anaesthesia
during the imaging. After all the images had been ob-
tained, the mice were sacrificed, and any lesions were
documented and photographed. The tumour nodules
found on post mortem examination served as the refer-
ence standard for evaluating the images. By choosing dif-
ferent points in time for the imaging, a broad spectrum
of different nodule sizes was observed. Lesions were
measured post mortem using a calliper, and the volume
of tumours was calculated according to the formula
length × width × height × 0.5. In face of some uncertainty
remaining with regard to as to the true tumour volume
in very small lesions, tumour nodules were categorised
into relatively broad size ranges in order to avoid
“pseudo-accuracy”. The tumour lesions were divided
into five groups according to size (group 1 1–2 mm,
group 2 >2–4 mm, group 3 >4–6 mm, group 4 >6-8 mm,
group 5 >8–10 mm). Each nodule was also classed ac-
cording to its specific location (e.g. liver surface or
colonic region).
Bioluminescence imaging
Bioluminescence imaging was performed with a cooled
CCD camera coupled to a light intensifier unit (Hama-
matsu). In vitro tests had been performed prior to the
actual study in order to correlate cell number and
semi-quantitative light signal gained by the CCD cam-
era. These investigations were intended to document
both transfection integrity and the linearity range of the
imaging device (data not given) [8].
D-luciferin (sodium salt, SYNCHEM) was dissolved in
sterile water to give a concentration of 15 mg/ml, filter
sterilised and stored at −70 °C. The mice were injected
i.p. with a mixture of 300 μl D-luciferin (15 mg/ml)
and 200 μl anaesthetic (82 % saline, 10 % Ketavet,
8 % Rompun) 10 min before imaging. We tried to
achieve the best possible intraperitoneal distribution
of the substrate. The puncture was carried out on the
linea alba, caudal to the umbilicus at an caudal angle
between 30° and 45° to avoid intraintestinal injection
and to protect other abdominal organs. Injections to
the peritoneum were performed slowly in 0.5 ml
medium with s-short subcutaneous needle and a 1 ml
“insulin” syringe using a potentially saturating dose of
D-luciferin. The distribution of the substrate was sup-
ported manually by mild massage and rotation of the
mouse around the longitudinal axis.
For the imaging, mice were placed on a gel cushion in a
dark box. Each mouse was recorded in the supine and lat-
eral positions. First, photographs of the mice were taken
in dimmed light. Then bioluminescent images were taken
with an exposure time of 10 s. The dimmed light images
were merged with the corresponding bioluminescent
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colours. Hamamatsu Simple PCI software was used for
image processing.
PET
PET imaging was performed using a Phillips MOSAIC
small animal scanner with a spatial resolution of 2.5 mm.
The system is based on 14,456 individual GSO crystals
with dimensions of 2 × 2 × 10 mm3, arranged in 52 rings
of 278 crystals each. The port diameter was 19.7 cm. The
transverse field of view was 12.8 cm, with an axial ex-
tent of 12.0 cm. The coincidence timing window was
12 ns; the standard energy window was between 410
and 665 keV.
The mice were given i.p. injections of 13 MBq of 18 F-
FDG. The i.p. route was preferred over i.v. administration
to prevent potential paravenous injections due to the very
small calibre of the murine tail veins which could have sig-
nificantly altered the biodistribution of 18 F-FDG in our
tumour model. Fueger et al. performed a comparison of i.v.
versus i.p. injection of 18 F-FDG and found a comparable
distribution of the tracer for intravenous and intraperito-
neal injection after 60 min. [9]. The prolonged uptake time
of 3 h was chosen to allow for optimal background clear-
ance. Anaesthetics were injected 10 min before im-
aging. The mice were placed in the prone position.
Scan time was 15 min, using an isotropic voxel size of
1 mm and a matrix of 128 × 128 × 120 voxels. All im-
ages were reconstructed with a fully three-dimensional it-
erative reconstruction algorithm (3D–Ramla). Axial images
were reformatted with coronal orientation using multipla-
nar reconstruction (MPR).
Image interpretation
Two observers (JS and HW, with 20 and 16 years imaging
experience, respectively) visually interpreted the PET and
BLI images. The two readers were blinded with respect to
the results of the post mortem examination. Any discrepan-
cies were resolved by consensus. The imaging results were
subsequently correlated with the post mortem findings. Le-
sions were classed as true positive, false positive or false
negative. It was not possible to calculate a meaningful true
negative fraction—either on the basis of the mice (because
all animals had at least one tumour at post mortem) or on
the basis of the lesions (because, in theory, there is an infin-
ite number of negative tumour lesions per mouse). Deter-
mination of the diagnostic performance was therefore
limited to the calculation of the sensitivity and the positive
predictive value (PPV).
Correlation of BLI signal and tumour volume post
mortem
A correlation between BLI light signal and tumour vol-
ume post mortem (“in vivo”) was performed on basis ofpara-pancreatic lesions. The area was chosen for analysis
because it was anatomically well defined, and the num-
ber of BLI positive lesions was comparatively high.
Statistics
The sensitivity of BLI and PET in relation to the post
mortem findings was calculated for mice as well as for
lesions. The PPV was calculated on a lesion-by-lesion
basis. The differences in terms of sensitivity and PPV
were analysed statistically using the McNemar’s test for
data related to the mice and the chi-square test for
lesion-by-lesion data. The correlation of BLI signal and
tumour volume post mortem (“in vivo”) was performed
using the Spearman rank correlation coefficient. A value
of p < 0.05 was taken to be statistically significant.
Results
Lesions and mice
All mice developed peritoneal carcinomatosis with simi-
lar patterns and extents by the time of death. Typical
sites of tumour nodules were the surface of the liver,
around the pancreas and the bowel mesentery. At post
mortem, a total of 82 lesions were found in 15 mice.
All but one mouse had one or more positive lesions in
PET imaging (sensitivity: 93 % (14/15)). Using BLI, all
mice had at least one detectable lesion (sensitivity 100 %
(15/15)). We recognised no unexpected low BLI signal in
an individual mouse that would suggest accidental intrain-
testinal administration of D-luciferin. The difference be-
tween PET and BLI was not significant (p value 0.50).
Accuracy according to the site of the lesion
Table 1 summarises the sensitivity of the imaging modal-
ities in detecting lesions according to the anatomical site.
Overall, 58 out of 82 lesions (sensitivity 71 %) were found
with PET versus 40 out of 82 lesions (sensitivity 49 %) with
BLI. The difference between PET and BLI was significant at
p < 0.05 (chi-square 8.2152; p value 0.004154).
With PET, we obtained seven false-positive sites (in five
mice) in the abdominal cavity and none with BLI. The posi-
tive predictive values were 0.89 % (58/65) for PET and
100 % (40/40) for BLI. The difference between PET and BLI
(chi-square 4.6154; p value 0.031686) was significant at a
level of p < 0.05.
Accuracy according to the size of the lesion
Lesion sizes ranged between 1 and 10 mm. Table 2 shows
the detection rate for the imaging methods in relation to
the size of the lesions. Overall, there was an obvious correl-
ation between lesion size and the detection rate seen for all
modalities. Despite its relatively limited spatial resolution
compared with BLI, however, PET with 18 F-FDG detected
even small nodules measuring 1–2 mm in 58 % of the cases
(Fig. 1). PET detected all nodules larger than 6 mm. False-
Table 1 Sensitivity for the detection of intraperitoneal lesions
with PET and BLI depending on the site of the tumour
n Site or region Volume range Sensitivity PET Sensitivity BLI
[mm3] [%] [%]
8 Injection site 0.3–9.0 63 (5/8) 100 (8/8)
2 Peritoneum 1.0–1.8 50 (1/2) 100 (2/2)
7 Diaphragm 0.1–1.8 14 (1/7) 0 (0/7)
13 Liver surface 0.5–3.0 85 (11/13) 8 (1/13)
1 Stomach 0.5 100 (1/1) 0 (0/1)
1 Duodenum 3.0 100 (1/1) 0 (0/1)
21 Jejunum 0.5–10.0 84 (16/21) 48 (10/21)
6 Colon 0.5–6.0 80 (4/6) 33 (2/6)
19 Pancreas 1.0–18 83 (15/19) 79 (15/19)
2 Uterus 1.8–3.0 100 (2/2) 100 (2/2)
2 Bladder 1.8–4.0 50 (1/2) 0 (0/2)
82 Total 0.1–18.0 74 (58/82)* 49 (40/82)*
The table shows the number of malignant lesions [n] with respect to different
sites, the volume range and the sensitivities for PET and BLI. The difference
between PET and BLI was significant at p < 0.05 (*chi-square 8.2152;
p value 0.004154)
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specific bowel activity (Fig. 2).
The detection of tumour nodules with BLI depended
greatly on the site of the lesion. Even larger nodules lo-
cated deep inside the peritoneal cavity were not delin-
eated, most likely due to the limited depth penetration
of the light (Fig. 3). However, small superficial nodules
measuring 1–2 mm were successfully detected.Correlation of BLI signal and tumour volume post
mortem
We found no significant correlation between BLI light
signal and tumour volume post mortem (“in vivo”) for
lesions in the para-pancreatic area. Even one larger le-
sion covered by the left liver lobe remained undetected
(Fig. 4).Table 2 Sensitivity for the detection of intraperitoneal lesions
by PET and BLI depending on tumour size
Size of the lesion n Sensitivity PET Sensitivity BLI
[%] [%]
0–2 mm 50 58 (29/50) 40(20/50)
>2–4 mm 18 88 (15/17) 47 (8/17)
>4–6 mm 7 88 (7/8) 75 (6/8)
>6–8 mm 3 100 (3/3) 100 (3/3)
>8–10 mm 4 100 (4/4) 75 (3/4)
Total 82 71 (58/82) 49 (40/82)
The table shows the sensitivities for the detection of intraperitoneal lesions
using PET and BLI with tumours of different sizes. There is a general
correlation between lesion size and detection rate with both modalitiesDiscussion
Early detection of peritoneal dissemination is essential
for adequate treatment planning in the initial staging
and follow-up of patients with gastric cancer. The
diminishing role of surgical reassessment in treated pa-
tients has increased the reliance on cross-sectional
imaging.
Accurate detection of peritoneal carcinomatosis by
non-invasive means is a challenge in studies on both ani-
mals and humans. The peritoneum of the abdomen and
pelvis provides a large surface area for microscopic seed-
ing [10]. Tumour cells may grow on free peritoneal sur-
faces or invaginate the peritoneal folds over the
mesentery or omentum, making some tumours ex-
tremely difficult to detect.
A number of imaging modalities for small animals
evolved over the last decade and were successfully ap-
plied in numerous studies [8]. These modalities included
also preclinical methods such as BLI. Functional imaging
using PET was also introduced and scanners constructed
for small animal use. These modalities, which differ sig-
nificantly in temporal and spatial resolution, have inher-
ently different technical requirements. To the best of
our knowledge, however, few data comparing PET and
BLI have yet been obtained in a single animal study. Our
aim, therefore, was to evaluate the sensitivity and overall
accuracy of these methods in detecting peritoneal car-
cinomatosis in a mouse model.PET
PET using 18 F-FDG was more sensitive than BLI in our
study. In general, PET detected lesions independently of
the site but with a clear correlation to the size of the le-
sions. As shown in Table 1, lesions on the peritoneal sur-
face were detected in 60 % of cases (6/10), whereas only
one out of seven lesions (14 %) was identified on the dia-
phragm. This low detection rate might be explained by
the size of the nodules, since all undetected lesions mea-
sured less than 1 mm. This agrees with the results of
Kondo et al. [11], who reported a limited sensitivity of
18 F-FDG PET for lesions smaller than 4 mm in their
animal model.
We observed seven false-positive sites using PET, all of
which were found in views of the bowel mesentery.
These sites can probably be attributed to focal uptake of
18 F-FDG in the bowel, which is non-specific in nature
and not related to tumour tissue. 18 F-FDG uses the
same initial pathway as glucose and the uptake is there-
fore highly dependent on the presence of glucose trans-
porters in the cell membrane. These transporters are
present in tumour cells but also in many other tissues.
18 F-FDG is also taken up by inflammatory cells, which
may explain false-positive findings in a clinical setting.
Fig. 1 Small peritoneal lesion in the small bowel mesentery (white arrow) (a). The tumour measured 1.5 mm in diameter and was detected only
with PET (b). The lesion was probably too deep in the abdominal cavity to be detected with BLI (c)
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and false-positive results due to focal uptake in non-
malignant tissue might be regarded as potential limita-
tions of PET. However, 18 F-FDG is still the most com-
mon tracer used in oncology for both clinical purposes
and experimental setups. More specific tracers such as
18 F-FLT still need to be validated.
Bioluminescence imaging
Bioluminescence imaging is a modality that perfectly
suits the needs of small animal imaging. It is quick, quite
easy to handle, and relatively inexpensive [12]. Biolumin-
escence imaging has been shown to be sensitive in vari-
ous animal studies and has also been used to monitor
tumour progression and relapse [13].
In our study, however, BLI was relatively insensitive
compared with PET. This finding is, most likely, attrib-
uted mainly to light scattering and absorption (amount
of tissue between cancer cells and CCD camera). When
tumours are growing as a well-defined focal lesion close
to the surface e.g. after flank injection, a good correl-
ation between BLI signal and actual tumour mass isFig. 2 A 2.5 mm nodule in the para-pancreatic region found at post morte
BLI (c) (white arrows). There were two false-positive sites on PET that couldusually observed. This correlation is reduced in setups in
which multiple lesions grow relatively dispersed in the
abdomen, as it is the case in our intraperitoneal model
[14]. The correlation between BLI light signal and
tumour volume post mortem (“in vivo”) was not signifi-
cant. BLI negative lesions resulted not only in a decrease
in sensitivity but obviously have also substantial contri-
bution to non-optimal correlation of light signal and
tumour size (Fig. 4).
As might be expected, the sensitivity in the abdominal
cavity depended on the site of the lesion. As shown in
Table 1, all nodules attached to the peritoneum (n = 10)
were detected by BLI. This high detection rate is prob-
ably explained by the superficial position of the lesions.
Nodules shielded by dense structures or organs such as
the liver frequently remained undetected. This might ex-
plain why none of the nodules on the diaphragm and
only one lesion on the liver (1/13) could be seen.
It is important to notice, however, that the sensitivity of
BLI is potentially dependent on various other factors, such
as luciferase expression levels, transfection stability, oxy-
genation and tumour viability, as well as the performancem (white arrow) (a). The lesion was detected easily with PET (b) and
not be documented at post mortem (small white arrows) (b)
Fig. 3 Post mortem finding of a 5.5-mm para-pancreatic lesion and a 4-mm lesion in small bowel mesentery (white arrows) (a). Both nodules were
detected with PET (b). The lesion in small bowel mesentery remained undetected with BLI, most likely due to the site being covered by other
bowel structures (c)
Stollfuss et al. EJNMMI Research  (2015) 5:44 Page 6 of 8and the setting of the camera. Some uncertainty may
also remain with respect to a perfectly homogeneous
distribution of the implanted tumour cells and the
substrate D-luciferin in peritoneal cavity.
In principle, the substrate D-luciferin can be adminis-
tered to animals using intraperitoneal (i.p.), subcutane-
ous (s.c.) and intravenous (i.v.) injections. After i.p.
injection D-luciferin is absorbed by the peritoneum and
reaches luciferase-expressing tissues mainly via blood-
stream. In fact, variations in absorption rate through the
peritoneum may distort the reproducibility of signal
quantification [15]. A biodistribution study of radiola-
beled D-luciferin demonstrated higher uptake in the
gastrointestinal organs (pancreas and spleen) after i.p.Fig. 4 Correlation of BLI light signal (mean grey level intensity) and tum
No significant correlation could be noted (Spearman rank correlation c
interpretation of the trend line. One larger lesion (16 mm3) remained uinjection than after i.v. injection. In addition, direct dif-
fusion, other than the delivery via systemic circulation,
may cause preferential distribution of D-luciferin in
superficial intraperitoneal tumours close to the injection
site [16]. However, the contribution of direct diffusion of
the substrate to the overall signal is probably low owing
to poor membrane permeability of D-luciferin [17].
Therefore, we think that i.p. administration may gener-
ally lead to overestimation of luciferase activity of IP tu-
mours relative to extraabdominal tumours rather than
causing “false” negative results in intraperitoneal lesions.
However, s.c. injection of D-luciferin may be an alterna-
tive to i.p. injection for BLI of xenografts in nude mice
particularly for tumours with weaker signals and whenour volume in the para-pancreatic area determined post mortem.
oefficient r = 0.2978, n.s.). A mild correlation is suggested by visual
ndetected because it was covered by the left liver lobe
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studies [18].
Quantification of the BLI light signal may also be dis-
torted due to technical reasons associated with CCD im-
aging. Larger tumours may show increased optical
density and thus increased quenching of the signal as
well as reduced availability of substrate to the tumour
core compared to smaller tumours. This implies that
tumour load may be underestimated when using BLI
in vivo. The duration of light exposure to the camera is
another potential factor influencing the sensitivity of the
system. The exposure time is characterised by a trade-
off between imaging depth and overexposure of superfi-
cial lesions. The parameter is therefore specific for the
experimental setup and technical equipment. The expos-
ure time in our study was derived from experience ob-
tained in previous studies [8], which means that it was
somewhat arbitrary in nature.
Although the correlation between light signal and
tumour volume is not significant, changes in tumour
mass relative to the initial BLI signal can still be accur-
ately quantified when a uniform position of the animals
towards the camera on the different imaging days is
achieved. The BLI signal is, thereby, normalised to the
baseline of each individual animal during the course of
intervention [14].
Limitations
Our study does have certain limitations. First, the num-
bers of animals and lesions undergoing imaging were
relatively small. On the other hand, the pre-test prob-
ability of the presence of peritoneal tumour was quite
high, because all mice had at least one tumour on post
mortem examination. In consequence, our study did not
address the true “sensitivity” of the methods used for de-
tection but derived only relative sensitivities. For this
reason, we cannot determine whether our findings could
be extrapolated to a non-selected patient population or
to other malignancies. Furthermore, the lack of a true
negative fraction did not allow the specificity to be de-
termined. The limited application of BLI in human stud-
ies is also obvious.
Conclusions
PET was the more sensitive compared to BLI for detect-
ing early peritoneal carcinomatosis in our mouse model.
The sensitivity of BLI largely depended on the site of the
lesions relative to the imaging device.
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